Compound News and Research

RSS

Bionomics, Ironwood partner to develop and commercialize novel anti-anxiety compound

Ironwood Pharmaceuticals, Inc. and Bionomics Limited today announced that they entered into a collaboration, research, and licensing agreement that will enable Ironwood to develop and commercialize Bionomics' investigational anti-anxiety compound BNC210 and other related compounds.

5 Jan 2012

Positive results from Alkermes ALKS 5461 phase 1/2 study on MDD

Alkermes plc today announced positive topline results from a phase 1/2 study of ALKS 5461, a novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression.

5 Jan 2012

Lithocholic acid can kill several types of cancer cells

Lithocholic acid (LCA), naturally produced in the liver during digestion, has been seriously underestimated. A study published in the journal Oncotarget shows that LCA can kill several types of cancer cells, such as those found in some brain tumors and breast cancer.

5 Jan 2012

Arrowhead receives FDA IND approval for Adipotide obesity drug

Arrowhead Research Corporation, a nanomedicine company with development programs in oncology and obesity, today announced that the Investigational New Drug Application (IND) for its first obesity drug candidate, Adipotide, was accepted by the U.S. Food and Drug Administration allowing the initiation of a clinical trial to test the safety of the compound.

5 Jan 2012

$Viamet commences VT-464 Phase 1/2 trial in castration-refractory prostate cancer$

Viamet commences VT-464 Phase 1/2 trial in castration-refractory prostate cancer

Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1/2 clinical trial of VT-464, an oral, potent and lyase-selective CYP17 inhibitor for the treatment of castration-refractory prostate cancer.

4 Jan 2012

Re-admission rates high among U.S. heart attack patients: Study

According to new research from U.S health experts, Americans who have a severe form of a heart attack are far more likely to be readmitted to the hospital than people from 16 other countries with the same kind of heart attack.

4 Jan 2012

Scientists discover chemical compound that inhibits poxviruses from replicating

A team of scientists from Boston University School of Medicine (BUSM) have identified a novel compound that inhibits viruses from replicating. The findings, which are published online in the Journal of Virology, could lead to the development of highly targeted compounds to block the replication of poxviruses, such as the emerging infectious disease Monkeypox.

4 Jan 2012

Alexion to acquire 100% of capital stock of Enobia

Alexion Pharmaceuticals, Inc. and Enobia Pharma Corp. today announced that the companies have signed a definitive agreement under which Alexion will acquire 100% of the capital stock of Enobia.

29 Dec 2011

Scientists identify molecular player critical to proper working of important health proteins

Half the drugs used today target a single class of proteins - and now scientists have identified an important molecular player critical to the proper workings of those proteins critical to our health.

28 Dec 2011

Fluoride has dramatic effects on bacteria inside the mouth

Regular use of fluoride-containing toothpaste and mouthwash has long been known to strengthen the enamel on teeth. But new research by Howard Hughes Medical Institute (HHMI) scientists finds that fluoride also has dramatic effects on bacteria inside the mouth -- including those that form plaque and can cause cavities.

23 Dec 2011

D12-PGJ3 compound can cure leukemia

A compound produced from fish oil that appears to target leukemia stem cells could lead to a cure for the disease, according to Penn State researchers. The compound -- delta-12-protaglandin J3, or D12-PGJ3 -- targeted and killed the stem cells of chronic myelogenous leukemia, or CML, in mice, said Sandeep Prabhu, associate professor of immunology and molecular toxicology in the Department of Veterinary and Medical Sciences.

23 Dec 2011

FLT-PET imaging can effectively detect mantle cell lymphoma

Positron emission tomography (PET) and a molecular imaging agent that captures the proliferation of cancer cells could prove to be a valuable method for imaging a form of Non-Hodgkin's disease called mantle cell lymphoma, a relatively rare and devastating blood cancer.

22 Dec 2011

Scientists discover N-cadherin as promising therapeutic target for pancreatic cancer

Often, and without much warning, pancreatic cancer cells slip through the endothelial cells, head into the blood and out to other parts of the body to metastasize, making it one of the deadliest and hardest to treat cancers today.

22 Dec 2011

Researchers discover how c-MYC facilitates tumor growth

Cancer cells are essentially immortal. The acquisition of an unlimited capacity to divide - the process of immortalization - is a central event in the genesis of tumors. Normally, cells are subject to stringent mechanisms which control their proliferation. Together these ensure that pre-malignant cells are induced to enter a senescent, non-dividing state or to undergo apoptosis, i.e. commit suicide.

22 Dec 2011

Yissum introduces novel technology for manufacturing an anti-malaria drug in tobacco

Combating malaria is one of the eight Millennium Development Goals described in the United Nations Millennium Declaration signed by all UN members at the year 2000. A key intervention to control malaria is prompt and effective treatment with artemisinin-based combination therapies.

19 Dec 2011

Cohera Medical secures over $25 million in Series C financing through private investors

Cohera Medical, a leading innovator and developer of absorbable surgical adhesives and sealants, announced today that it has secured over $25 million Series C financing through private investors. A total of $16.5 million was raised through existing investors and over $9 million was raised through new investors, which significantly bolstered the round.

19 Dec 2011